# Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

> **NCT01721876** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 666 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Placebo
- **DRUG:** Volasertib
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT01721876
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-29
- **Primary completion:** 2014-08-12
- **Final completion:** 2021-05-28
- **Target enrollment:** 666 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721876, "Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT01721876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*